Rankings Pharma & medtech Initiator Pharma
Initiator Pharma
45
15070100
A view of the same findings, not a new score. How it works
The model found several serious problems. That does not mean the stock will fall.
Biggest deductions
- Margin−10
- Funding−7
- Quality of growth−6
Strengths
- Patent protection and non-dilutive study funding+1
Speculative profile
A penny stock under DKK 3. The asymmetry rating is separate from the Bjarvik score and is not a recommendation.
- Asymmetry (1–10)
- 4
- Price
- 1.35 DKK
- Market value
- DKK 92m
- Cash runway
- 11 months
- Cash / debt
- 26.0 / 14.7m SEK
- Dilution, 12 months
- +22%
Bull case
Vulvodynia data at the turn of the year shows clear pain relief. It is a condition with no approved treatment and many patients, and women's health attracts partners. A licence agreement with payment on signing funds the company, and the ED programme comes along as a bonus. Then the market cap could go from approx. SEK 140m to 0.5–1bn (3–7x).
Bear case
The vulvodynia study shows no effect with single doses. Then only the ED programme without a partner is left, cash runs out in 2027, and a MAC loan of up to approx. DKK 21m must be repaid. An emergency issue at DKK 0.5–1 could halve or cut the share price to a third.
Catalysts
- 20 Nov 2026Q3 report with status of recruitment for the vulvodynia study and cashgradual stockanalysis.com
- end of 2026Topline data from phase 2a with pudafensine in vulvodynia (24 women, placebo-controlled crossover)binary biostock.se
- no date from the companyLicense or partner agreement for pudafensine (ED or FSD/vulvodynia)binary inderes.fi
Risk of going to zerohigh – one molecule, a binary readout at year-end, cash into 2027 and a growing loan to MAC
Next financingAmounts in SEK, converted from DKK: cash DKK 17.1m and debt DKK 9.7m. The company's own net burn is about DKK 4.6m per quarter (H1: cash fell 9.2m, and 7.5m was drawn on the MAC credit), because MAC pays for the study. The company says the money lasts 'into 2027'. New capital (issue or licence deal) is needed around H1 2027, and the MAC loan must be repaid over 3 years if it is not converted.
Warrants & convertiblesMAC Clinical Research has a convertible credit of up to GBP 2.5m (about DKK 21m). It can be converted into shares at 40% above TERP in the 2025 rights issue, far above today's price. Otherwise it becomes a 3-year loan at 1% after the study. About DKK 9.7m has been drawn. No outstanding warrant series found.
Insiders, last 12 monthsNo insider purchases or sales found in the sources searched (not fully verified in FI's insider register). CEO Claus Elsborg Olesen owns c. 1.07m shares (c. 2%).
Largest ownersLinc AB 19.7%, Adrigo Asset Management 8.1%, Nordnet Pensionsförsäkring about 5%, Avanza Pension about 5%, CEO Claus Olesen about 2% (Affärsvärlden).
Circio check(1) Small market cap: yes, approx. DKK 92m. (2) Hot theme: partial, women's health and non-opioid pain treatment are getting attention, but are not hot like AI or obesity. (3) Upcoming milestones: yes, vulvodynia topline at the end of 2026. (4) Major partner: no, MAC is a CRO that funds the study, not a pharma partner. (5) Funding for 2+ years: no, only into 2027. (6) Price near the bottom: partial, −39% in a year and the lowest market cap since 2021, but no capitulation.
Why this asymmetryThe binary vulvodynia readout in about 3 months gives real upside, because the market is large and without treatment. But the study is small and uses single doses, and ED data has not been sellable for years. The cash and the MAC loan mean that a negative result hits hard.
How the score is built
From 100 to 45, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 3 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 1.99 SEK
- Median analyst target
- 5.52 SEK
- Upside to median
- +178.1%
- Analysts
- 2
- Target range
- 5.10 – 5.94 SEK
- 52-week change
- −38%
- P/E (trailing)
- n/a
- Forward P/E
- n/a
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 4 findings−23 of −30
- −10MarginNo revenue. The net loss is DKK 28.2m (TTM) vs 13.7m in 2025, so it has doubled. The operating loss was DKK 20.9m in H1 2026 alone.
- −6Quality of growthPudafensine showed a significant effect in phase 2b against organic erectile dysfunction. The new track in vulvodynia is a small phase 2a study (24 women, single doses, crossover), which can only give proof of concept.
- −3MoatNew patents (two from the EPO in August 2026, Hong Kong in July and an FSD patent in February) protect the molecule. But the erectile dysfunction market is dominated by cheap generic PDE5 inhibitors, so the commercial moat is weak outside the niche of men who do not respond to PDE5 inhibitors.
- −4Capital allocationAfter many years of spending, the rest of the pipeline (including IP2018) was closed in April 2026, and everything is bet on one molecule. The loss has doubled while the company has only one employee.
Price
Today's multiples against the company's own history and its peers. · 2 findings−4 of −35
- −2Multiples vs own historyP/B 11.5 vs 4.7–29 in 2021–2025. The figure is distorted by a small equity base, but the stock is not cheap measured on book value. The market value (SEK 145m) is the lowest since 2021.
- −2PeersEV of about SEK 134m for a phase 2b asset without a partner is in line with Nordic biotech peers at the same stage. The discount reflects that nobody has wanted to license the ED program.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 6 findings−23 of −35
- −7FundingCash was DKK 17.1m at 30/6 (26.3m at the turn of the year). The company writes that the money lasts 'into 2027'. A new issue is likely in H1 2027, especially if vulvodynia data disappoint.
- −4Debt from the MAC agreementMAC Clinical Research is funding the vulvodynia study with a convertible credit of up to GBP 2.5m (about DKK 21m). The conversion price is 40% above TERP in the 2025 issue and is far above today's price, so the credit will probably become a 3-year loan at 1%. Debt is already DKK 9.7m, and a full draw exceeds the current cash.
- −4DilutionThe share count has risen from 43.8m (2021) to 68.5m (+56%), of which +22% after the rights issue of SEK 48m in 2025.
- −4PartnerThe positive phase 2b data in erectile dysfunction has not led to a licence deal in the years since. That is a warning sign about how attractive the programme is to the big companies.
- −3Clinical riskAll the value now depends on topline data from the vulvodynia study (24 patients, single doses) at the end of 2026. In case of a negative result the company is left with only the ED programme without a partner.
- −1Share price riskThe price has fallen 39% over a year and is below both the 50-day average (2.35) and the 200-day average (2.82). Turnover is low (about DKK 145k/day).
Plus
Only documented strengths. · 1 finding+1 of +15
- +1Patent protection and non-dilutive study fundingThree new patent approvals for pudafensine in 2026 (EPO ×2 and Hong Kong). The vulvodynia study is paid for by MAC without an issue.
Caveats
What the score does not capture, or where the data is weak.
Danish company traded in SEK on First North Stockholm, but reporting in DKK. The amounts in the penny item are converted to SEK (DKK 1 ≈ SEK 1.52). No revenue and no analysts (forecast 404); 1 employee. Market cap fits: 68.45m shares × SEK 2.04 = SEK 140m ≈ DKK 92m, as at Nordnet. P/B 11.5 is meaningless because equity is only DKK 8.5m. Insider trading in the last 12 months has not been fully examined.
Also in Pharma & medtech
The highest scores in the same industry.
